Citadel Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-66,100
| Closed | -$621K | – | 11860 |
|
|
2020
Q3 | $621K | Buy |
66,100
+24,000
| +57% | +$228K | ﹤0.01% | 6904 |
|
|
2020
Q2 | $322K | Buy |
42,100
+25,000
| +146% | +$191K | ﹤0.01% | 7808 |
|
|
2020
Q1 | $106K | Sell |
17,100
-4,400
| -20% | -$38.8K | ﹤0.01% | 8602 |
|
|
2019
Q4 | $262K | Sell |
21,500
-36,600
| -63% | -$400K | ﹤0.01% | 7801 |
|
|
2019
Q3 | $671K | Sell |
58,100
-10,400
| -15% | -$109K | ﹤0.01% | 6250 |
|
|
2019
Q2 | $684K | Buy |
68,500
+54,500
| +389% | +$588K | ﹤0.01% | 6312 |
|
|
2019
Q1 | $180K | Sell |
14,000
-24,900
| -64% | -$371K | ﹤0.01% | 8285 |
|
|
2018
Q4 | $591K | Sell |
38,900
-12,200
| -24% | -$232K | ﹤0.01% | 6155 |
|
|
2018
Q3 | $1.02M | Buy |
51,100
+21,800
| +74% | +$496K | ﹤0.01% | 5504 |
|
|
2018
Q2 | $571K | Buy |
29,300
+12,400
| +73% | +$274K | ﹤0.01% | 6153 |
|
|
2018
Q1 | $341K | Sell |
16,900
-16,100
| -49% | -$272K | ﹤0.01% | 6531 |
|
|
2017
Q4 | $437K | Buy |
33,000
+6,900
| +26% | +$104K | ﹤0.01% | 5862 |
|
|
2017
Q3 | $482K | Buy |
26,100
+3,600
| +16% | +$67.1K | ﹤0.01% | 5395 |
|
|
2017
Q2 | $414K | Buy |
22,500
+6,500
| +41% | +$129K | ﹤0.01% | 5391 |
|
|
2017
Q1 | $361K | Sell |
16,000
-500
| -3% | -$12K | ﹤0.01% | 5592 |
|
|
2016
Q4 | $574K | Sell |
16,500
-1,400
| -8% | -$41.8K | ﹤0.01% | 4692 |
|
|
2016
Q3 | $439K | Sell |
17,900
-14,600
| -45% | -$365K | ﹤0.01% | 5055 |
|
|
2016
Q2 | $777K | Buy |
32,500
+8,800
| +37% | +$202K | ﹤0.01% | 3897 |
|
|
2016
Q1 | $555K | Sell |
23,700
-5,600
| -19% | -$133K | ﹤0.01% | 4276 |
|
|
2015
Q4 | $885K | Buy |
29,300
+23,200
| +380% | +$750K | ﹤0.01% | 3728 |
|
|
2015
Q3 | $242K | Sell |
6,100
-3,100
| -34% | -$192K | ﹤0.01% | 5878 |
|
|
2015
Q2 | $635K | Buy |
9,200
+3,900
| +74% | +$245K | ﹤0.01% | 4607 |
|
|
2015
Q1 | $290K | Sell |
5,300
-2,400
| -31% | -$114K | ﹤0.01% | 5697 |
|
|
2014
Q4 | $328K | Buy |
7,700
+3,500
| +83% | +$126K | ﹤0.01% | 5303 |
|
|
2014
Q3 | $134K | Buy |
4,200
+4,100
| +4,100% | +$87.4K | ﹤0.01% | 6124 |
|
|
2014
Q2 | $2K | Sell |
100
-2,100
| -95% | -$38.8K | ﹤0.01% | 7843 |
|
|
2014
Q1 | $43K | Sell |
2,200
-2,000
| -48% | -$42.5K | ﹤0.01% | 6879 |
|
|
2013
Q4 | $102K | Sell |
4,200
-3,400
| -45% | -$80K | ﹤0.01% | 5598 |
|
|
2013
Q3 | $163K | Buy |
7,600
+4,500
| +145% | +$106K | ﹤0.01% | 4960 |
|
|
2013
Q2 | $69K | Buy |
+3,100
| New | +$68.3K | ﹤0.01% | 5476 |
|
Citadel Advisors's AMAG Position: Q4 2020 in Review
Citadel Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 134,552 shares — an estimated $1.26M sold.
Citadel Advisors first reported a position in AMAG in Q2 2013 and held it in 25 quarters. The position peaked at $21.4M in Q2 2017. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Citadel Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 134,552 AMAG Pharmaceuticals shares in Q4 2020, an estimated $1.26M.
- Citadel Advisors first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 25 quarters.
- Citadel Advisors's AMAG Pharmaceuticals position peaked at $21.4M in Q2 2017.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.